Press release
Animal Nutrition
November 12, 2019

Evonik declares force majeure for its methionine production in Antwerp

• Outage of hydrocyanic acid supply for methionine production in Antwerp, Belgium
• Company declares Force Majeure
• Company does not expect an impact on earnings

Following an issue with hydrocyanic acid (HCN) supply for methionine production, Evonik has temporarily shut down its methionine manufacturing plants in Antwerp.

Dr. Emmanuel Auer, Head of Animal Nutrition Business Line at Evonik explained: “Unfortunately we have suffered an outage of HCN supply for our methionine production. The supply failure impacts both of our methionine plants in Antwerp. We have decided to send a Force Majeure notification to our customers and suppliers with immediate effect, in accordance with our contracts.”

Evonik is investigating repair scenarios and is expecting to have a solution very soon. Meanwhile Evonik is trying to meet customer demand with stock materials and does not expect any impact on earnings. The technical teams are working hard to solve the problem and customers will be kept informed as the situation develops.

Company information

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.

About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around €4.6 billion in 2018.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.